Test your candidates

The main deliverable of UM CURE 2020 is the identification and validation in the preclinical setting of novel therapeutic strategies for metastatic UM. From the beginning of the project, currently approved or new inhibitors of pathways known to be dysregulated in UM are being tested in the available preclinical models. This will be complemented by additional preclinical studies in a second phase of the project, that target newly-discovered actionable biochemical and immunological targets and pathways, and by performing assays in the newly-developed preclinical models more representative of the metastatic disease.

Contact us if you believe you have a promising candidate molecule in your pipeline that should be tested. 

Follow us